EFFECT OF THE SGLT2 INHIBITOR DAPAGLIFLOZIN ON RENAL FUNCTION AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN ELDERLY PATIENTS WITH EARLY DIABETIC KIDNEY DISEASE

Objective To investigate the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on renal function and renin-angiotensin-aldosterone system (RAAS) in elderly patients with early diabetic kidney disease (DKD). Methods A total of 97 elderly patients with type 2 diabetes mellitus (T2DM) who attended our hospital from September 1, 2019 to August 1, 2021 were enrolled, and according to urinary albumin-to-creatinine ratio (UACR), they were divided into normal UACR group and early DKD group. A random number table was further used to determine whether each patient in the above two groups was treated with dapagliflozin. Finally, all patients were divided into normal-UACR dapagliflozin group (group A), normal-UACR control group (group B), early-DKD dapagliflozin group (group C), and early-DKD control group (group D), and these four groups were compared in terms of the changes in related clinical indices at 1 year after treatment. Results After 1 year of treatment, group A had significant change